Literature DB >> 20569697

A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer.

Roberta Pang1, Wai Lun Law, Andrew C Y Chu, Jensen T Poon, Colin S C Lam, Ariel K M Chow, Lui Ng, Leonard W H Cheung, Xiao R Lan, Hui Y Lan, Victoria P Y Tan, Thomas C Yau, Ronnie T Poon, Benjamin C Y Wong.   

Abstract

Recent evidence suggests that a subpopulation of cancer cells, cancer stem cells (CSCs), is responsible for tumor growth in colorectal cancer. However, the role of CSCs in colorectal cancer metastasis is unclear. Here, we identified a subpopulation of CD26(+) cells uniformly present in both the primary and metastatic tumors in colorectal cancer patients with liver metastasis. Furthermore, in patients without distant metastasis at the time of presentation, the presence of CD26(+) cells in their primary tumors predicted distant metastasis on follow-up. Isolated CD26(+) cells, but not CD26(-) cells, led to development of distant metastasis when injected into the mouse cecal wall. CD26(+) cells were also associated with enhanced invasiveness and chemoresistance. Our findings have uncovered a critical role of CSCs in metastatic progression of cancer. Furthermore, the ability to predict metastasis based on analysis of CSC subsets in the primary tumor may have important clinical implication as a selection criterion for adjuvant therapy. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20569697     DOI: 10.1016/j.stem.2010.04.001

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  229 in total

1.  Cancer: Chemotherapy counteracted.

Authors:  Urban Emmenegger; Robert S Kerbel
Journal:  Nature       Date:  2010-12-02       Impact factor: 49.962

Review 2.  Materials and microfluidics: enabling the efficient isolation and analysis of circulating tumour cells.

Authors:  Joshua M Jackson; Małgorzata A Witek; Joyce W Kamande; Steven A Soper
Journal:  Chem Soc Rev       Date:  2017-07-17       Impact factor: 54.564

Review 3.  Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches.

Authors:  Cristóbal Aguilar-Gallardo; Emily Cecilia Rutledge; Ana M Martínez-Arroyo; Juan José Hidalgo; Santiago Domingo; Carlos Simón
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

4.  Circulating Tumor Cells and Colorectal Cancer.

Authors:  Joshua E Allen; Wafik S El-Deiry
Journal:  Curr Colorectal Cancer Rep       Date:  2010-10-01

Review 5.  Cancer stem cells: a new framework for the design of tumor therapies.

Authors:  Boyan K Garvalov; Till Acker
Journal:  J Mol Med (Berl)       Date:  2010-10-02       Impact factor: 4.599

6.  Highly enriched CD133(+)CD44(+) stem-like cells with CD133(+)CD44(high) metastatic subset in HCT116 colon cancer cells.

Authors:  Ke-li Chen; Feng Pan; Heng Jiang; Jian-fang Chen; Li Pei; Fang-wei Xie; Hou-jie Liang
Journal:  Clin Exp Metastasis       Date:  2011-07-13       Impact factor: 5.150

Review 7.  Cancer Stem Cells in Squamous Cell Carcinoma.

Authors:  Zhe Jian; Alexander Strait; Antonio Jimeno; Xiao-Jing Wang
Journal:  J Invest Dermatol       Date:  2016-11-24       Impact factor: 8.551

8.  "The development tumor model" to study and monitor the entire progression of both primary and metastatic tumors.

Authors:  Enrico Brognaro
Journal:  Tumour Biol       Date:  2013-11-10

9.  G9a/RelB regulates self-renewal and function of colon-cancer-initiating cells by silencing Let-7b and activating the K-RAS/β-catenin pathway.

Authors:  Shih-Ting Cha; Ching-Ting Tan; Cheng-Chi Chang; Chia-Yu Chu; Wei-Jiunn Lee; Been-Zen Lin; Ming-Tsan Lin; Min-Liang Kuo
Journal:  Nat Cell Biol       Date:  2016-08-15       Impact factor: 28.824

10.  The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites.

Authors:  Hua Gao; Goutam Chakraborty; Ai Ping Lee-Lim; Qianxing Mo; Markus Decker; Alin Vonica; Ronglai Shen; Edi Brogi; Ali H Brivanlou; Filippo G Giancotti
Journal:  Cell       Date:  2012-08-17       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.